Introduction of the special issue “How does the prostate cancer microenvironment affect the metastatic process and/or treatment outcome?”

References

[1] Mason M.Getting better at treating prostate cancer: what clinicians should want from scientists.J Cancer Metastasis Treat2017;3:271-7

[2] Maitland NJ.Getting closer to prostate cancer patients: what scientists should want from clinicians.J Cancer Metastasis Treat2017;3:262-70

[3] Pippione AC,Pors K,Lolli ML.Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention.J Cancer Metastasis Treat2017;3:328-61

[4] Morgan R.HOX transcription factors and the prostate tumor microenvironment.J Cancer Metastasis Treat2017;3:278-87

[5] Falconer RA.Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting.J Cancer Metastasis Treat2017;3:315-27

[6] Shephard AP,Clayton A.Prostate cancer exosomes as modulators of the tumor microenvironment.J Cancer Metastasis Treat2017;3:288-301

[7] Frame FM,Klein S,Suman R,Mann VM,Maitland NJ.Tumor heterogeneity and therapy resistance - implications for future treatments of prostate cancer.J Cancer Metastasis Treat2017;3:302-14

[8] McKenna DJ,Pors K.Current challenges and opportunities in treating hypoxic prostate tumors.J Cancer Metastasis Treat2018;4:11

[9] Ibrahim AIM,Frame FM,Pors K.Expression and regulation of aldehyde dehydrogenases in prostate cancer.J Cancer Metastasis Treat2018;4:44